By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need.
Based on its industry-leading expertise in retinal neuroprotection, ONL is developing first-in-class treatments for serious, vision-threatening retinal diseases and conditions. The company possesses a strong and wide-ranging intellectual property portfolio around both the Fas pathway and the composition of its drug candidates, as well as experienced management and expert advisory teams with decades of experience in drug development and retinal disease.
ONL’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways. ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, an acute condition for which the company has been granted orphan drug designation by the FDA. In addition, the company is currently developing ONL1204 in geographic atrophy associated with age-related macular degeneration, glaucoma, and other acute and chronic indications.
Vision
To help patients see the future.
Values
Mission
To develop first-in-class therapeutics to protect the vision of patients with retinal disease.